Amber Freed's son Maxwell was diagnosed with SLC6A1 at 18 months old. SLC6A1 is a rare genetic disorder that causes seizures, severe movement and speech disorders, and intellectual disability. When Freed went looking for treatments, she found almost nothing. The condition was so rare it barely had a research community. There was one published study. She read it "probably 50 times."
Most parents in that position grieve, adapt, and accept. Freed declared war.
In 2018, she founded SLC6A1 Connect, a patient-led organization built from scratch to do what the pharmaceutical industry had decided was not profitable enough to pursue. She made her family's tragedy as public as possible -- social media hashtags, a family support group, a website, attendance at medical conferences where she wore a sign that read "Help SLC6A1." She turned her son's diagnosis into a campaign.
"I decided to fight like a mother," Freed said.
That phrase is not metaphor. Freed identified gene replacement therapy as the most promising treatment path for Maxwell. The problem was that no one was developing it, because the patient population was too small to attract pharmaceutical investment. So Freed went and built the market herself.
She tracked down the authors of that single published study. "I need to find these 10 parents," she said, referring to the families documented in the research. She found them. She connected them. She built a network of families who had been isolated by the rarity of their children's condition and turned them into an organized advocacy force.
She partnered with Taysha Gene Therapies to develop a treatment. She bought mutant mice from China so researchers would have animal models to test on. She offered to name the gene therapy after the highest-bidding donor for $1 million, turning fundraising into a naming-rights auction for a cure that did not yet exist.
Years of this work led to a breakthrough. Maxwell became one of the first patients to receive the treatment -- a gene therapy for a condition so rare it did not even have a widely recognized name when Freed started fighting.
The ripple of Freed's campaign extends through every family with a child affected by SLC6A1 and, more broadly, through every rare disease community watching a mother prove that patient-led organizations can move the needle when industry will not. She did not wait for a pharmaceutical company to notice her son. She built the infrastructure that made noticing unavoidable.
At Hero.me, we talk about the Service Paradox -- the idea that you conquer your own dragon by helping someone else conquer theirs. Freed's dragon was a genetic disorder with no treatment and no research community. She conquered it by building a community of families, funding research, buying lab mice, and wearing a sign at conferences. She did not do this for Maxwell alone. She did it for every child with SLC6A1, born and unborn. By filling her mind with the needs of all those families, she built something large enough to attract the scientific and pharmaceutical attention that one family alone could never have commanded. That is not advocacy. That is a mother who reverse-engineered a drug development pipeline because no one else was going to do it.